¡Ya estamos en !
Descubre más
WWB
Windward Bio Group
Acerca de: Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. Its flagship program is WIN378, a potentially novel, long-acting, anti-TSLP monoclonal antibody. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bi-specific, which has therapeutic application across immunological diseases.
Noticias
Positivo
Neutral
Negativo
Sentimiento
3 meses
Positivo
0%
Neutral
0%
Negativo
0%
No hemos recibido artículos de noticias recientes sobre WWB.
Gráficos de precios implementados con Lightweight Charts™